Venus Remedies Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Venus Remedies Share Price

1,797.5082.41 (4.81%)

Closed
As On: 12 Jun, 2026, 03:56 PM IST
As On: 12 Jun, 2026, 03:53 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	1,749.90
High	1,800.80
Low	1,706.80
Prev Close	1,715.10
Volume	2,46,228
VWAP(₹)	1,773.34

Key Metrics

PE Ratio(x)	23.37
EPS - TTM(₹)	76.91
MCap(₹ Cr.)	2,402.72
MCap Rank	77
PB Ratio(x)	3.29
Div Yield(%)	0.56
Face Value(₹)	10.00
52W High(₹)	1,800.80
52W Low(₹)	416.00
MCap/Sales	1.43
Beta(1 Month)	0.78
BV/Share(₹)	496.56

Venus Remedies share price insights

All Debts Paid-off
Company has become debt free for the first time since last 5 years. (Source: Consolidated Financials)
Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 16.95% outperformed its 3 year CAGR of 11.28%. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 11.52% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Venus Remedies Share Price Update
Venus Remedies Ltd. share price moved up by 4.81% from its previous close of Rs 1,715.10. Venus Remedies Ltd. stock last traded price is 1,797.50
Share Price Value
Today/Current/Last 1,797.501,801.25
Previous Day 1,715.101,716.45

Found Insights useful?

Venus Remedies Share Price Returns

1 Day	4.81%
1 Month	92.93%
3 Months	93.8%
1 Year	303.3%
3 Years	670.8%
5 Years	475.48%

Venus Remedies Share Recommendations

Recent Recos

Target₹107
Organizationmanasjaiswal.com
BUY

Target₹107
Organizationmanasjaiswal.com
BUY

View all Stock Recommendations

News & Analysis

View all Venus Remedies Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	264.35	182.78	194.46	140.59	201.73
Total Income Growth (%)	44.63	-6.01	38.32	-30.31	12.77
Total Expenses	202.73	149.30	167.96	127.98	170.68
Total Expenses Growth (%)	35.79	-11.11	31.24	-25.02	10.83
EBIT	61.62	33.48	26.50	12.61	31.05
EBIT Growth (%)	84.05	26.34	110.15	-59.39	24.75
Profit after Tax (PAT)	47.49	25.58	20.13	9.60	21.00
PAT Growth (%)	85.65	27.07	109.69	-54.29	7.14
EBIT Margin (%)	23.31	18.32	13.63	8.97	15.39
Net Profit Margin (%)	17.96	13.99	10.35	6.83	10.41
Basic EPS (₹)	35.53	19.14	15.06	7.18	15.71

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	263.65	182.36	194.33	139.85	200.81
Total Income Growth (%)	44.58	-6.16	38.96	-30.36	15.22
Total Expenses	206.08	149.55	168.73	125.15	175.98
Total Expenses Growth (%)	37.80	-11.37	34.82	-28.88	21.43
EBIT	57.57	32.81	25.60	14.70	24.83
EBIT Growth (%)	75.46	28.16	74.15	-40.80	-15.43
Profit after Tax (PAT)	43.45	24.92	19.24	11.69	14.79
PAT Growth (%)	74.36	29.52	64.59	-20.96	-38.58
EBIT Margin (%)	21.84	17.99	13.17	10.51	12.36
Net Profit Margin (%)	16.48	13.67	9.90	8.36	7.37
Basic EPS (₹)	32.51	18.64	14.40	8.75	11.07

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	782.18	668.84	613.03	565.83	606.96
Total Revenue Growth (%)	16.95	9.10	8.34	-6.78	6.91
Total Expenses	648.02	606.93	568.39	527.90	570.55
Total Expenses Growth (%)	6.77	6.78	7.67	-7.48	5.14
Profit after Tax (PAT)	102.78	45.31	28.49	26.57	40.72
PAT Growth (%)	126.81	59.05	7.25	-34.77	-34.07
Operating Profit Margin (%)	17.43	9.56	7.43	6.88	6.16
Net Profit Margin (%)	13.35	6.99	4.73	4.78	6.80
Basic EPS (₹)	76.89	33.90	21.31	19.88	30.86

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	780.19	660.24	586.53	547.84	583.61
Total Revenue Growth (%)	18.17	12.57	7.06	-6.13	9.62
Total Expenses	649.52	591.08	539.88	507.51	538.94
Total Expenses Growth (%)	9.89	9.48	6.38	-5.83	4.70
Profit after Tax (PAT)	99.31	52.56	30.50	28.96	48.99
PAT Growth (%)	88.93	72.34	5.30	-40.87	-9.74
Operating Profit Margin (%)	16.99	10.81	8.11	7.50	7.76
Net Profit Margin (%)	12.91	8.21	5.30	5.38	8.51
Basic EPS (₹)	74.29	39.32	22.82	21.67	37.12

All figures in Rs Cr, unless mentioned otherwise

Insights

Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 16.95% outperformed its 3 year CAGR of 11.28%. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 11.52% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	853.71	715.72	626.82	601.08	579.82
Total Assets Growth (%)	19.28	14.18	4.28	3.67	4.31
Total Liabilities	189.96	154.77	139.27	140.74	139.37
Total Liabilities Growth (%)	22.74	11.13	-1.05	0.98	-10.41
Total Equity	663.75	560.95	487.55	460.34	440.45
Total Equity Growth (%)	18.33	15.05	5.91	4.52	10.03
Current Ratio (x)	2.44	3.31	4.53	3.91	3.00
Total Debt to Equity (x)	0.00	0.00	0.08	0.09	0.10
Contingent Liabilities	0.00	47.92	37.46	32.91	10.83

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	876.06	713.21	641.26	608.89	578.66
Total Assets Growth (%)	22.83	11.22	5.32	5.22	5.82
Total Liabilities	186.43	123.72	132.67	130.84	129.25
Total Liabilities Growth (%)	50.69	-6.75	1.40	1.23	-11.85
Total Equity	689.63	589.49	508.59	478.05	449.41
Total Equity Growth (%)	16.99	15.91	6.39	6.37	12.30
Current Ratio (x)	2.56	4.14	4.96	4.38	3.20
Total Debt to Equity (x)	0.00	0.00	0.08	0.08	0.09
Contingent Liabilities	0.00	47.92	37.46	32.91	10.83

All figures in Rs Cr, unless mentioned otherwise

Insights

All Debts Paid-off
Company has become debt free for the first time since last 5 years. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	155.76	86.44	37.29	36.63	41.00
Net Cash used in Investing Activities	-181.56	-76.25	-7.21	-50.83	-16.63
Net Cash flow from Financing Activities	-3.12	-1.02	-1.08	-0.57	-9.48
Net Cash Flow	-32.41	8.57	27.74	-22.04	14.38
Closing Cash & Cash Equivalent	25.11	57.52	48.96	21.21	43.26
Closing Cash & Cash Equivalent Growth (%)	-56.35	17.50	130.79	-50.96	49.78
Total Debt/ CFO (x)	0.00	0.02	1.11	1.15	1.04

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	151.09	83.10	35.38	28.05	40.90
Net Cash used in Investing Activities	-181.57	-76.20	-6.94	-50.81	-16.65
Net Cash flow from Financing Activities	-1.39	-	-	-	-9.13
Net Cash Flow	-31.87	6.90	28.44	-22.76	15.12
Closing Cash & Cash Equivalent	23.54	55.41	48.51	20.07	42.83
Closing Cash & Cash Equivalent Growth (%)	-57.51	14.22	141.70	-53.14	54.59
Total Debt/ CFO (x)	0.00	0.00	1.09	1.38	0.95

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 181.56 cr for investing activities which is an YoY increase of 138.12%. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	15.48	8.07	5.84	5.77	9.24
Return on Capital Employed (%)	19.39	10.69	8.17	7.37	7.57
Return on Assets (%)	12.03	6.33	4.54	4.41	7.02
Interest Coverage Ratio (x)	3,996.75	1,291.82	759.66	239.55	146.41
Asset Turnover Ratio (x)	0.98	0.97	0.98	0.90	1.01
Price to Earnings (x)	10.74	8.84	15.31	8.15	8.83
Price to Book (x)	1.66	0.71	0.89	0.47	0.82
EV/EBITDA (x)	6.72	3.81	5.75	2.91	5.00
EBITDA Margin (%)	20.77	13.04	11.83	12.69	11.76

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	14.40	8.91	5.99	6.05	10.90
Return on Capital Employed (%)	18.20	11.37	8.20	7.52	9.00
Return on Assets (%)	11.33	7.36	4.75	4.75	8.46
Interest Coverage Ratio (x)	0.00	0.00	0.00	0.00	0.00
Asset Turnover Ratio (x)	0.97	0.94	0.92	0.91	1.02
Price to Earnings (x)	11.12	7.62	14.31	7.48	7.34
Price to Book (x)	1.60	0.68	0.86	0.45	0.80
EV/EBITDA (x)	6.92	3.55	5.64	2.83	4.51
EBITDA Margin (%)	20.20	14.19	12.55	13.33	13.43

Insights

ROE Outperforming 5 Year Average
Company delivered ROE of 15.48% in year ending Mar 31, 2026 outperforming its 5 year avg. of 9.33%. (Source: Consolidated Financials)

Found Financials useful?

Technicals

Buy/Sell Signals
No Data Available
Price Analysis
No Data Available
Pivot Levels
R1 - Pivot
-
S1 -
R2 - S2 -
R3 - S3 -
Average True Range
5 Days 14 Days 28 Days
- - -

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Venus Remedies	23.37	3.62	15.48	19.39	12.03	11.28	17.43	13.35	76.89	2.44	0.00	0.00
Ind-Swift Labs	34.18	1.02	2.99	4.33	2.47	-17.67	9.58	6.44	4.95	3.83	0.01	-0.28
Kopran Ltd	34.09	1.65	4.85	7.97	2.83	7.09	6.57	3.77	5.33	1.51	0.29	2.29
Anuh Pharma	19.43	2.26	11.65	15.43	7.36	13.16	7.08	5.31	4.10	2.22	0.00	0.00
Kilitch Drug	21.91	2.39	10.78	13.15	6.59	19.85	18.77	12.52	8.91	1.83	0.32	3.70
Add More

Annual Ratios (%)

Choose from Peers

Zim Laboratories
SMS Lifesciences Ind
Albert David
Medicamen Bio
Lyka Labs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 55,81,997 41.76 % 0.00
Pledge 0 0.00 % 0.00
FII 3,73,740 2.80 % 0.55
DII 1,60,978 1.20 % 0.16
Others 72,50,273 54.24 % -0.71
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 41.76 41.76 41.76 41.76
Pledge 0.00 0.00 0.00 0.00
FII 2.80 2.25 1.86 2.25
DII 1.20 1.03 0.75 0.11
Mutual Funds 0.00 0.00 0.00 0.00
Others 54.24 54.96 55.63 55.88

Mutual Funds Ownership

No Data Available

Venus Remedies Top Searches

Corporate Actions

Recent
General Meeting
-
May 26, 2026
Final
100%
May 26, 2026
Board Meeting
Audited Results, Final Dividend & A.G.M.
May 15, 2026

Announced on	Meeting on
May 15, 2026	May 26, 2026
Audited Results, Final Dividend & A.G.M.
Jan 19, 2026	Jan 29, 2026
Quarterly Results & Others
Oct 27, 2025	Nov 10, 2025
Quarterly Results
Jul 22, 2025	Aug 01, 2025
Quarterly Results
Jun 27, 2025	Jul 08, 2025
Others

Dividends
Announced on Ex-Date Dividend%
May 20, 2013 Sep 23, 2013 30%
Jun 21, 2012 Sep 20, 2012 30%
Jul 26, 2011 Sep 22, 2011 30%
May 26, 2026 - 100%
Jun 02, 2014 - 30%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available

AGM/EGM Meetings

Announced on	Meeting on
May 26, 2026	Aug 20, 2026
-
Jul 24, 2025	Aug 22, 2025
-
Aug 06, 2024	Sep 23, 2024
Book closure from Sep 17, 2024 to Sep 23, 2024
Jul 14, 2023	Aug 24, 2023
A.G.M.
Nov 09, 2020	Dec 02, 2020
Book closure from Nov 26, 2020 to Dec 2, 2020

About Venus Remedies

Venus Remedies Ltd., incorporated in the year 1989, is a Small Cap company (having a market cap of Rs 2,402.72 Crore) operating in Pharmaceuticals sector.

Venus Remedies Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue and Research & Development for the year ending 31-Mar-2024.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 264.35 Crore, up 44.63 % from last quarter Total Income of Rs 182.78 Crore and up 31.04 % from last year same quarter Total Income of Rs 201.73 Crore. Company has reported net profit after tax of Rs 47.49 Crore in latest quarter.

The company’s top management includes Mr.Pawan Chaudhary, Dr.(Mrs.)Manu Chaudhary, Mr.Peeyush Jain, Mr.Akshansh Chaudhary, Mr.Ashutosh Jain, Dr.Anil Kumar, Mr.Jagdish Chander Sharma, Mr.N P S Monga, Mr.Navdeep Sud, Dr.(Mrs.)Savita Gupta, Mr.Pawan Chaudhary, Mrs.Neha Kodan. Company has Vinod Kumar & Associates as its auditors. As on 31-03-2026, the company has a total of 1.34 Crore shares outstanding.

Venus Remedies Share Price Today is Rs. 1797.50. On previous day, the Venus Remedies Share Price (NSE) closed at Rs. 0.0, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 41.76% of the stake in Venus Remedies shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Venus Remedies stocks was 2.8% as compared to 2.25% in Dec 2025 with increase of 0.55%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 1.2% as compared to 1.03% in Dec 2025 with increase of 0.17%. Out of the total DII holdings in Venus Remedies shares 0.0% was held by mutual funds. The rest including public held is 54.24%. Venus Remedies stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Venus Remedies Dividend: Ever since 1989, Venus Remedies dividends has been paid out around 12 times. As on 12 Jun, 2026, 03:56 PM IST, The overall dividend yield for Venus Remedies stands at 0.58%. The last dividend paid was on null (Rs. 10.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 76.91.

Venus Remedies Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 264.35 Cr. of sales and 44.63% of quarterly net profit, there have been multiple ups and downs in the Venus Remedies stock prices in the past few weeks. For example, Venus Remedies stock price on 5th of June 2026 was around Rs. 1633.5. Venus Remedies share price now stands at an average of Rs. 1797.50. Judging by last week's performance, stock is in down trend.

Venus Remedies has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Venus Remedies share.

Historical Prices and Performance:
Venus Remedies, incorporated in 1989 is a Small Cap company (with a market cap of Rs. 2402.72) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Venus Remedies stock was 15.48%, 8.07%, 5.84%, 5.77% and 9.24% respectively.
The Venus Remedies share gave a 3 year return of 670.8% as compared to Nifty 50 which gave a return of 26.99%.
Venus Remedies announced 100.0% final dividend on null.

Key Metrics:
PE Ratio of Venus Remedies is 22.3
Prices/Sales Ratio of Venus Remedies is 1.43
Price/Book Ratio of Venus Remedies is 3.45

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Venus Remedies, major competitors and peers include Ind-Swift Labs, Kopran Ltd, Anuh Pharma and Kilitch Drug. As of Dec 2025, the dividend yield of Venus Remedies stands at 0.58% while Ind-Swift Labs, Kopran Ltd, Anuh Pharma and Kilitch Drug stand at 0.0%, 1.65%, 1.88% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 22.3 and 3.45 respectively.

Leadership of Venus Remedies :
Ajeet Kapoor is Vice President & Head
Pawan Chaudhary is Chief Financial Officer
Neha Kodan is Co. Secretary & Compl. Officer
Pawan Chaudhary is Chairman & Managing Director
Manu Chaudhary is Joint Managing Director
Peeyush Jain is Deputy Managing Director
Ashutosh Jain is Executive Director
Akshansh Chaudhary is Executive Director
Savita Gupta is Independent Director
N P S Monga is Independent Director
Navdeep Sud is Independent Director
Jagdish Chander Sharma is Independent Director
Anil Kumar is Independent Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

-

Address

S.C.O. 857, C. No. 10,2nd Floor, NAC Manimajra,Chandigarh, Chandigarh - 160101

Contact

investorgrievance@venusremedies.com

http://www.venusremedies.com

Executive Leadership

PC

Pawan Chaudhary

Chairman & Managing Director

MC

Manu Chaudhary

Joint Managing Director

PJ

Peeyush Jain

Deputy Managing Director

AC

Akshansh Chaudhary

Executive Director

Show More

Auditors

J K Jain & Associates

Vinod Kumar & Associates

FAQs about Venus Remedies share

1. What's Venus Remedies share price today and what are Venus Remedies share returns ?
Venus Remedies share price is Rs 1,797.50 as on 12 Jun, 2026, 03:56 PM IST. Venus Remedies share price is up by 4.81% based on previous share price of Rs. 1633.5.
2. What's the market capitalization of Venus Remedies?
Within the Pharmaceuticals sector, Venus Remedies stock has a market cap rank of 77. Venus Remedies has a market cap of Rs 2,402.72 Cr.
3. What is the PE & PB ratio of Venus Remedies?
The PE ratio of Venus Remedies stands at 22.3, while the PB ratio is 3.45.
4. What is Venus Remedies's 52 week high / low?
Venus Remedies share price saw a 52 week high of Rs 1,800.80 and 52 week low of Rs 416.00.
5. What are the returns for Venus Remedies share?
Return Performance of Venus Remedies Shares:
- 1 Week: Venus Remedies share price moved up by 10.04%

Top Gainers

As on 04:06 PM | 12 Jun 2026

1,028.70

714.90 (227.82%)

Netweb Technologies

4,587.40

2780.60 (153.90%)

Syrma SGS Technology

1,266.70

737.70 (139.45%)

14.90

8.12 (119.76%)

4,942.50

2633.90 (114.09%)

Top Losers

As on 03:58 PM | 12 Jun 2026

Tata Investment

665.90

-6218.10 (-90.33%)

339.50

-2678.10 (-88.75%)

757.55

-3315.15 (-81.40%)

403.30

-1723.50 (-81.04%)

Authum Investment

530.15

-1967.65 (-78.78%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.